The expanded application of CAR-T cell therapy for the treatment of multiple non-tumoral diseases

References

[1] Adabi N, Pordel S, Rezaee MA et al. Application of CAR-T cell technology in autoimmune diseases and human immunodeficiency virus infection treatment. J Gene Med 2023;25:e3484.

[2] Aghajanian H, Kimura T, Rurik JG et al. Targeting cardiac fibrosis with engineered T cells. Nature 2019;573:430–3.

[3] Amor C, Feucht J, Leibold J et al. Senolytic CAR T cells reverse senescence-associated pathologies. Nature 2020;583:127–32.

[4] Anthony-Gonda K, Bardhi A, Ray A et al. Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model. Sci Transl Med 2019;11:eaav5685.

[5] Baker DJ, Arany Z, Baur JA et al. CAR T therapy beyond cancer: the evolution of a living drug. Nature 2023;619:707–15.

[6] Beheshti SA, Shamsasenjan K, Ahmadi M et al. CAR Treg: a new approach in the treatment of autoimmune diseases. Int Immunopharmacol 2022;102:108409.

[7] Bertoletti A, Tan AT. HBV as a target for CAR or TCR-T cell therapy. Curr Opin Immunol 2020;66:35–41.

[8] Blat D, Zigmond E, Alteber Z et al. Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells. Mol Ther 2014;22: 1018–28.

[9] Bohne F, Chmielewski M, Ebert G et al. T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes. Gastroenterology 2008;134:239–47.

[10] Davila ML, Bouhassira DC, Park JH et al. Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies. Int J Hematol 2014;99:361–71.

[11] Dragon AC, Zimmermann K, Nerreter T et al. CAR-T cells and TRUCKs that recognize an EBNA-3C-derived epitope presented on HLA-B*35 control Epstein-Barr virus-associated lymphoproliferation. J ImmunoTher Cancer 2020;8:e000736.

[12] Ellebrecht CT, Bhoj VG, Nace A et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science 2016;353:179–84.

[13] Fischer JW, Bhattarai N. CAR-T cell therapy: mechanism, management, and mitigation of inflammatory toxicities. Front Immunol 2021;12:693016.

[14] Fransson M, Piras E, Burman J et al. CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery. J Neuroinflammation 2012;9:112.

[15] Ghanem MH, Bolivar-Wagers S, Dey B et al. Bispecific chimeric antigen receptors targeting the CD4 binding site and high-mannose Glycans of gp120 optimized for anti-human immunodeficiency virus potency and breadth with minimal immunogenicity. Cytotherapy 2018;20:407–19.

[16] Granit V, Benatar M, Kurtoglu M et al. MG-001 Study Team. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study. Lancet Neurol 2023;22:578–90.

[17] Guo G, He W, Zhou Z et al. PreS1- targeting chimeric antigen receptor T cells diminish HBV infection in liver humanized FRG mice. Virology 2023;586:23–34.

[18] Haghikia A, Hegelmaier T, Wolleschak D et al. Anti-CD19 CAR T cells for refractory myasthenia gravis. Lancet Neurol 2023;22:1104–5.

[19] Hale M, Mesojednik T, Romano Ibarra GS et al. Engineering HIV-Resistant, Anti-HIV chimeric antigen receptor T cells. Mol Ther 2017;25:570–9.

[20] Jiang VC, Hao D, Jain P et al. TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma. Mol Cancer 2022;21:185.

[21] Kansal R, Richardson N, Neeli I et al. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. Sci Transl Med 2019;11:eaav1648.

[22] Kruse RL, Shum T, Tashiro H et al. HBsAg-redirected T cells exhibit antiviral activity in HBV-infected human liver chimeric mice. Cytotherapy 2018;20:697–705.

[23] Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer 2021;21:145–61.

[24] Leibman RS, Richardson MW, Ellebrecht CT et al. Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor. PLoS Pathog 2017;13:e1006613.

[25] Liu L, Patel B, Ghanem MH et al. Novel CD4-based bispecific chimeric antigen receptor designed for enhanced anti-HIV potency and absence of HIV entry receptor activity. J Virol 2015;89:6685–94.

[26] Lu J, Jiang G. The journey of CAR-T therapy in hematological malignancies. Mol Cancer 2022;21:194.

[27] Ma M, Badeti S, Geng K et al. Efficacy of targeting SARS-CoV-2 by CAR-NK cells. bioRxiv 2020.

[28] Mackensen A, Muller F, Mougiakakos D et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med 2022;28:2124–32.

[29] Maude SL, Laetsch TW, Buechner J et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 2018;378:439–48.

[30] Mougiakakos D, Kronke G, Volkl S et al. CD19-Targeted CAR T cells in refractory systemic lupus erythematosus. N Engl J Med 2021;385:567–9.

[31] Muller F, Boeltz S, Knitza J et al. CD19-targeted CAR T cells in refractory antisynthetase syndrome. Lancet 2023;401:815–8.

[32] Mylvaganam G, Yanez AG, Maus M et al. Toward T cell-mediated control or elimination of HIV reservoirs: lessons from cancer immunology. Front Immunol 2019;10:2109.

[33] Narayan V, Barber-Rotenberg JS, Jung IY et al. Prostate Cancer Cellular Therapy Program Investigators. PSMA-targeting TGFbeta-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med 2022;28:724–34.

[34] Olbrich H, Theobald SJ, Slabik C et al. Adult and cord blood-derived high-affinity gB-CAR-T cells effectively react against human cytomegalovirus infections. Hum Gene Ther 2020;31:423–39.

[35] Proff J, Brey CU, Ensser A et al. Turning the tables on cytomegalovirus: targeting viral Fc receptors by CARs containing mutated CH2-CH3 IgG spacer domains. J Transl Med 2018;16:26.

[36] Qi J, Ding C, Jiang X et al. Advances in developing CAR T-cell therapy for HIV cure. Front Immunol 2020;11:361.

[37] Qi C, Gong J, Li J et al. Claudin182-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat Med 2022;28:1189–98.

[38] Qu C, Zhang H, Cao H et al. Tumor buster - where will the CAR-T cell therapy ‘missile’ go? Mol Cancer 2022;21:201.

[39] Quintarelli C, Orlando D, Boffa I et al. Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma. Oncoimmunology 2018;7:e1433518.

[40] Radichev IA, Yoon J, Scott DW et al. Towards antigen-specific Tregs for type 1 diabetes: construction and functional assessment of pancreatic endocrine marker, HPi2-based chimeric antigen receptor. Cell Immunol 2020;358:104224.

[41] Ruella M, Xu J, Barrett DM et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med 2018;24:1499–503.

[42] Rurik JG, Tombacz I, Yadegari A et al. CAR T cells produced in vivo to treat cardiac injury. Science 2022;375:91–6.

[43] Sautto GA, Wisskirchen K, Clementi N et al. Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein. Gut 2016;65:512–23.

[44] Seif M, Einsele H, Loffler J. CAR T cells beyond cancer: hope for immunomodulatory therapy of infectious diseases. Front Immunol 2019;10:2711.

[45] Sermer D, Brentjens R. CAR T-cell therapy: full speed ahead. Hematol Oncol 2019;37:95–100.

[46] Slabik C, Kalbarczyk M, Danisch S et al. CAR-T cells targeting Epstein-Barr Virus gp350 validated in a humanized mouse model of EBV infection and lymphoproliferative disease. Mol Ther Oncolytics 2020;18:504–24.

[47] Tenspolde M, Zimmermann K, Weber LC et al. Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes. J Autoimmun 2019;103:102289.

[48] Ward DE, Fay BL, Adejuwon A et al. Chimeric antigen receptors based on low affinity mutants of FcepsilonRI Re-direct T cell specificity to cells expressing membrane IgE. Front Immunol 2018;9:2231.

[49] Watanabe N, Mo F, McKenna MK. Impact of manufacturing procedures on CAR T cell functionality. Front Immunol 2022;13:876339.

[50] Yang D, Sun B, Li S et al. NKG2D-CAR T cells eliminate senescent cells in aged mice and nonhuman primates. Sci Transl Med 2023;15:eadd1951.

[51] Yoon J, Schmidt A, Zhang AH et al. FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T-and B-cell responses to FVIII. Blood 2017;129:238–45.

[52] Zhang L, Sosinowski T, Cox AR et al. Chimeric antigen receptor (CAR) T cells targeting a pathogenic MHC class II:peptide complex modulate the progression of autoimmune diabetes. J Autoimmun 2019;96:50–8.

[53] Zhang PF, Xie D, Li Q. Chimeric antigen receptor T-cell therapy beyond cancer: current practice and future prospects. Immunotherapy 2020;12:1021–34.

[54] Zhang K, Chen H, Li F et al. Bright future or blind alley? CAR-T cell therapy for solid tumors. Front Immunol 2023;14:1045024.

[55] Zhen A, Peterson CW, Carrillo MA et al. Long-term persistence and function of hematopoietic stem cell-derived chimeric antigen receptor T cells in a nonhuman primate model of HIV/AIDS. PLoS Pathog 2017;13:e1006753.

[56] Zhu T, Xiao Y, Meng X et al. Nanovesicles derived from bispecific CAR-T cells targeting the spike protein of SARS-CoV-2 for treating COVID-19. J Nanobiotechnol 2021;19:391.

RIGHTS & PERMISSIONS

The Author(s) 2023. Published by Oxford University Press on behalf of Higher Education Press.